𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease

✍ Scribed by Sean Lilienfeld

Book ID
109105592
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
198 KB
Volume
8
Category
Article
ISSN
1080-563X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The social consequences for families wit
The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment
✍ Anders Wimo; Bengt Winblad; Margareta Grafstrom 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 2 views

The social consequences of Alzheimer's disease are highlighted in this review with regard to impact on family situation, a changing treatment context caused by demographic changes, reorganization of long-term care, a ®nancial crisis in the public health systems and the introduction of antidementia d

A multinational, randomised, 12-week stu
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

Donepezil for the symptomatic treatment
Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials
✍ Anne Whitehead; Carlos Perdomo; Raymond D. Pratt; Jacqueline Birks; Gordon K. Wi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 3 views

## Abstract ## Background The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD). ## Method A systematic review of individual patient data from Phase II and III do